Sphenopalatine ganglion stimulation after stroke, promising but not yet ready for adoption

Affiliations

¹ Department of Neurology, Stroke Unit, Oslo University Hospital, Oslo, Norway.
² Radcliffe Department of Medicine, University of Oxford, Oxford OX4 4GA, UK. Electronic address: gary.ford@rdm.ox.ac.uk.

Comment

Else Charlotte Sandset et al. Lancet. 2019.

. 2019 Jul 20;394(10194):189-190.

doi: 10.1016/S0140-6736(19)31412-6.

¹ Department of Neurology, Stroke Unit, Oslo University Hospital, Oslo, Norway.
² Radcliffe Department of Medicine, University of Oxford, Oxford OX4 4GA, UK. Electronic address: gary.ford@rdm.ox.ac.uk.

No abstract available

Comment on

An injectable implant to stimulate the sphenopalatine ganglion for treatment of acute ischaemic stroke up to 24 h from onset (ImpACT-24B): an international, randomised, double-blind, sham-controlled, pivotal trial.
Bornstein NM, Saver JL, Diener HC, Gorelick PB, Shuaib A, Solberg Y, Thackeray L, Savic M, Janelidze T, Zarqua N, Yarnitsky D, Molina CA; ImpACT-24B investigators. Bornstein NM, et al. Lancet. 2019 Jul 20;394(10194):219-229. doi: 10.1016/S0140-6736(19)31192-4. Epub 2019 May 24. Lancet. 2019. PMID: 31133406 Clinical Trial.